Galectin Therapeutics Inc. (NASDAQ:GALT) Director Marc Rubin acquired 7,000 shares of Galectin Therapeutics stock in a transaction on Friday, December 8th. The stock was acquired at an average price of $1.85 per share, with a total value of $12,950.00. Following the purchase, the director now directly owns 55,581 shares in the company, valued at $102,824.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Galectin Therapeutics Inc. (GALT) traded up $0.42 during mid-day trading on Friday, hitting $2.43. Galectin Therapeutics Inc. has a fifty-two week low of $0.88 and a fifty-two week high of $3.68.

Galectin Therapeutics (NASDAQ:GALT) last posted its quarterly earnings results on Tuesday, November 7th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.02. sell-side analysts forecast that Galectin Therapeutics Inc. will post -0.52 EPS for the current year.

A number of brokerages have issued reports on GALT. ValuEngine downgraded Galectin Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Thursday, September 21st. Zacks Investment Research downgraded Galectin Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday. Roth Capital reduced their price objective on Galectin Therapeutics from $10.00 to $3.00 and set a “buy” rating for the company in a research note on Thursday. Seaport Global Securities restated a “buy” rating and issued a $5.00 price objective on shares of Galectin Therapeutics in a research note on Friday, October 6th. Finally, HC Wainwright upped their price objective on Galectin Therapeutics from $3.50 to $6.00 and gave the company a “buy” rating in a research note on Tuesday, November 28th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. Galectin Therapeutics currently has a consensus rating of “Hold” and an average price target of $4.55.

Hedge funds have recently bought and sold shares of the company. Northern Trust Corp grew its stake in shares of Galectin Therapeutics by 4.4% during the 2nd quarter. Northern Trust Corp now owns 75,097 shares of the company’s stock worth $185,000 after acquiring an additional 3,176 shares during the period. Virtu KCG Holdings LLC grew its stake in shares of Galectin Therapeutics by 24.4% during the 2nd quarter. Virtu KCG Holdings LLC now owns 107,203 shares of the company’s stock worth $264,000 after acquiring an additional 21,008 shares during the period. Advisor Group Inc. grew its stake in shares of Galectin Therapeutics by 7.4% during the 3rd quarter. Advisor Group Inc. now owns 519,850 shares of the company’s stock worth $1,112,000 after acquiring an additional 35,850 shares during the period. Finally, Vanguard Group Inc. grew its stake in shares of Galectin Therapeutics by 18.2% during the 2nd quarter. Vanguard Group Inc. now owns 871,510 shares of the company’s stock worth $2,144,000 after acquiring an additional 134,165 shares during the period. Institutional investors own 11.07% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.watchlistnews.com/galectin-therapeutics-inc-galt-director-marc-rubin-acquires-7000-shares-of-stock/1756253.html.

About Galectin Therapeutics

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.

Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.